Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652181 | 0.86 | ACHE (0.53) | ALDH1A1MLYCDMEN1KMT2ATP53 | |
| SCHEMBL3876454 | 0.83 | CES2 (0.65) | CES2ALDH1A1NPSR1OPRM1OPRL1 | |
| SCHEMBL20870672 | 0.83 | CES2 (0.65) | CES2ALDH1A1NPSR1OPRM1OPRL1 | |
| SCHEMBL3652937 | 0.83 | MLYCD (0.55) | CES2MLYCD | |
| SCHEMBL15281239 | 0.83 | KMT2A (0.50) | CES2MLYCDMEN1KMT2ALMNA | |
| SCHEMBL9100653 | 0.82 | CES2 (0.62) | CES2ALDH1A1NPSR1OPRM1OPRL1 | |
| SCHEMBL2653922 | 0.82 | MLYCD (0.58) | CES2MLYCDMAOBMEN1KMT2A | |
| SCHEMBL19084700 | 0.81 | HDAC8 (0.59) | NPSR1MEN1KMT2APOLBLMNA | |
| SCHEMBL25216553 | 0.81 | CES2 (0.61) | CES2ALDH1A1NPSR1OPRM1OPRL1 | |
| SCHEMBL1852354 | 0.80 | MLYCD (0.73) | CES2MLYCDSRD5A2MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4215529-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoibio Inc. (KR) | 2023-07-26 | — | — | EP | disclosed |
| CN-116194111-A | Heteroaryl derivatives, process for preparing the same, and pharmaceutical compositions containing the same as active ingredient | 株式会社沃若诺伊生物 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022060196-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 보로노이바이오 주식회사 | 2022-03-24 | — | — | WO | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| EP-0854870-A4 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0863757-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| EP-0863757-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5792778-A | TREATMENT OF CYTOKINE MEDIATED DISEASES | MERCK & CO., INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0854870-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997047618-A1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997012876-A9 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997005877-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB4, ERBB2, ERBB3 | CES2 3749/4885ALDH1A1 2285/4885NPSR1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.